NDLI: Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis.

Please wait, while we are loading the content...

Psychometric properties of the Swedish version of the Scleroderma Health Assessment Questionnaire and the Cochin Hand Function Scale in patients with systemic sclerosis.

An updated meta-analysis of the Fc receptor-like 3 -169T/C polymorphism and rheumatoid arthritis risk.

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.

Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study.

TNF- modulates expression of the circadian clock gene Per2 in rheumatoid synovial cells.

Clinical features of a new disease concept, IgG4-related thyroiditis.

Biopsy findings in giant cell arteritis: relationship to baseline factors and corticosteroid treatment.

Abdominal discomfort in patients with rheumatoid arthritis is associated with physical and mental function, self-reported disease activity, and use of anti-inflammatory medication.

Silencing TNF- in macrophages and dendritic cells for arthritis treatment.

Monoclonal gammopathy of undetermined significance and anti-TNF- treatment: comments on the article by Smale and Lawson.

Year: 2013 Volume: 42 Issue: 3

Year: 2013 Volume: 42 Issue: 2

Year: 2013 Volume: 42 Issue: 1

Year: 2012 Volume: 126

Year: 2012 Volume: 41

Year: 2011 Volume: 125

Year: 2011 Volume: 40

Year: 2010 Volume: 124

Year: 2010 Volume: 39

Year: 2009 Volume: 38

Year: 2008 Volume: 37

Year: 1998 Volume: 27

Year: 1987 Volume: 16

Year: 1980 Volume: 9

Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Eriksson, C. Rantapää-Dahlqvist, S. Sundqvist, K. G.
Description	Country affiliation: Sweden Author Affiliation: Eriksson C ( Department of Clinical Immunology/Clinical Microbiology, Umea University, Umea, Sweden. catharina.eriksson@vll.se)
Abstract	OBJECTIVES: Chemokines are involved in leucocyte recruitment into inflammatory sites. The release of certain chemokines is augmented by tumour necrosis factor (TNF). Infliximab, a monoclonal antibody that blocks the effects of TNF, is used for treatment of rheumatoid arthritis (RA). The effect of TNF blockage on chemokines is not fully understood. The aim of this study was to analyse the effects on chemokines and their receptors on peripheral mononuclear cells of anti-TNF treatment in RA patients. METHOD: Twelve patients with established RA who started treatment with infliximab and nine patients with early RA treated with other anti-rheumatic drugs were followed clinically for 30 weeks and chemokine levels in blood samples were analysed along with chemokine receptor expression on the surface of T cells and monocytes. Nine healthy subjects were included as a control group. RESULTS: The chemokine CXCL10/IP-10 was significantly higher in RA patients than in healthy controls (p = 0.012). Two weeks after infliximab infusion, CXCL10/IP-10, CCL2/MCP-1, and CCL4/MIP-1ß had decreased significantly (p = 0.005, 0.037, and 0.028, respectively), and after 30 weeks of treatment, soluble CD26 was significantly increased (p = 0.050). Several chemokine receptors on T cells were elevated in RA patients at inclusion. The expression of CCR2 and CXCR1 on T cells decreased significantly after infliximab treatment. CONCLUSIONS: The chemokines CXCL10/IP-10, CCL2/MCP-1, and CCL4/MIP-1ß, mainly targeting the T-helper (Th)1 immune response, decreased after treatment with anti-TNF, suggesting a more pronounced effect on Th1 activity than on Th2-mediated response. Several chemokine receptors on blood T cells were elevated in RA patients, suggesting that they may be involved in the recruitment of T lymphocytes from the blood to affected tissues.
File Format	HTM / HTML
ISSN	03009742
e-ISSN	15027732
Journal	Scandinavian Journal of Rheumatology
Issue Number	4
Volume Number	42
Language	English
Publisher	Taylor & Francis
Publisher Date	2013-01-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Rheumatology Antibodies, Monoclonal Administration & Dosage Antirheumatic Agents Arthritis, Rheumatoid Blood Drug Therapy Chemokines Tumor Necrosis Factor-alpha Drug Effects Diagnosis Biological Markers Case-control Studies Cohort Studies Dose-response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Infliximab Receptors, Chemokine Risk Assessment Metabolism Comparative Study Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Rheumatology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.

Estimated medication costs of primary TNF antagonist failure in patients with rheumatoid arthritis.

Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.

Change in CXCL10 on treatment with methotrexate similar to that reported with infliximab: comments on the article by Eriksson et al.

Anti-TNF therapy.

Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.

The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.

Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.

Dose optimization of infliximab in patients with rheumatoid arthritis.

Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis.

Similar Documents

Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.

Estimated medication costs of primary TNF antagonist failure in patients with rheumatoid arthritis.

Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.

Change in CXCL10 on treatment with methotrexate similar to that reported with infliximab: comments on the article by Eriksson et al.

Anti-TNF therapy.

Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.

The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.

Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.

Dose optimization of infliximab in patients with rheumatoid arthritis.

Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis.